drugset / Trial / NCT04092673
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Timeline
- Start
- 2019-10-25
- Primary completion
- 2024-12-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | — |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Sotorasib | Small molecule | 960 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 600 mg | — |
| Subject | Zotatifin | Small molecule | — | Intravenous |